U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H9Cl3N2OS
Molecular Weight 359.6595
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRICLABENDAZOLE

SMILES

CSc1[nH]c2cc(c(cc2n1)Oc3cccc(c3Cl)Cl)Cl

InChI

InChIKey=NQPDXQQQCQDHHW-UHFFFAOYSA-N
InChI=1S/C14H9Cl3N2OS/c1-21-14-18-9-5-8(16)12(6-10(9)19-14)20-11-4-2-3-7(15)13(11)17/h2-6H,1H3,(H,18,19)

HIDE SMILES / InChI

Molecular Formula C14H9Cl3N2OS
Molecular Weight 359.6595
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: https://www.drugs.com/international/triclabendazole.html | https://www.drugs.com/mmx/triclabendazole.html | https://www.ncbi.nlm.nih.gov/pubmed/15259481 | https://www.ncbi.nlm.nih.gov/pubmed/26312936

Triclabendazole, (brand name Avomec, Egaten, etc) is a member of the benzimidazole family of anthelmintics used to treat liver flukes, specifically fascioliasis and paragonimiasis. Triclabendazole used routinely since 1983 in veterinary practice for the treatment of fascioliasis. It was not used in humans until the 1989 epidemic of fascioliasis near the Caspian Sea when Iranian authorities approved the use of the veterinary formulation to treat the infection. Fasciolicidal not only against the adult worms present in the biliary ducts, but also against the immature larval stages of Fasciola migrating through the hepatic parenchyma. Triclabendazole is shown to penetrate into liver flukes by transtegumentary absorption followed by inhibition of the parasite's motility, probably related to the destruction of the microtubular structure, resulting in the death of the parasite; the immobilizing effect is paralleled by changes in the parasite's resting tegumental membrane potential, strongly inhibiting the release of proteolytic enzymes, a process that appears critical to the survival of the parasite. Side effects are generally few, but can include abdominal pain and headaches. Biliary colic may occur due to dying worms. While no harms have been found with use during pregnancy, triclabendazole has not been well studied in this population. Triclabendazole is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. It is not commercially available in the United States.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
15 µM [IC50]
Conditions
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.34 μM
10 mg/kg 1 times / day multiple, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.16 μM
10 mg/kg 1 times / day multiple, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
1.16 μM
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.55 μM × h
10 mg/kg 1 times / day multiple, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.72 μM × h
10 mg/kg 1 times / day multiple, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
5.72 μM × h
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8 h
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3.3%
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg/kg 1 times / 8 hours multiple, oral
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 12-60 years
Health Status: unhealthy
Age Group: 12-60 years
Sex: M+F
Sources:
Other AEs: Abdominal pain, Headache...
Other AEs:
Abdominal pain (6.4%)
Headache (10.6%)
Dizziness (4.3%)
Jaundice (2.1%)
Sources:
10 mg/kg 1 times / 8 hours multiple, oral
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 4-68 years
Health Status: unhealthy
Age Group: 4-68 years
Sex: M+F
Sources:
Other AEs: Dizziness, Abdominal pain...
Other AEs:
Dizziness (5.4%)
Abdominal pain (1.3%)
Diarrhea (1.3%)
Fever (1.9%)
Sources:
10 mg/kg 1 times / 8 hours multiple, oral
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 5-54 years
Health Status: unhealthy
Age Group: 5-54 years
Sex: M+F
Sources:
Other AEs: Headache, Abdominal pain...
Other AEs:
Headache (5.7%)
Abdominal pain (5.7%)
Vomiting (2.9%)
Diarrhea (2.9%)
Sources:
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Other AEs: Abdominal pain, Biliary colic...
Other AEs:
Abdominal pain (grade 3, 1.2%)
Biliary colic (grade 1-2, 49%)
Jaundice (grade 1-2, 7.2%)
Epigastric pain (grade 1-2, 42.7%)
Nausea (grade 1-2, 8.5%)
Fever (grade 1-2, 8.5%)
Pruritus (grade 1-2, 6.1%)
Urticaria (grade 1-2, 2.4%)
Sources:
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Other AEs: Abdominal pain, Hyperhidrosis...
Other AEs:
Abdominal pain (93%)
Hyperhidrosis (25%)
Nausea (18%)
Urticaria (11%)
Vomiting (7%)
Headache (14%)
Pruritus (4%)
Musculoskeletal chest pain (4%)
Decreased appetite (18%)
Diarrhea (7%)
Sources:
15 mg/kg single, oral
Recommended
Dose: 15 mg/kg
Route: oral
Route: single
Dose: 15 mg/kg
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Other AEs: Bilirubin increased, AST increased...
Other AEs:
Bilirubin increased (6.8%)
AST increased (4.5%)
Alkaline phosphatase increased (4.2%)
ALT increased (3%)
Sources:
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Other AEs: Urticaria, Nausea...
Other AEs:
Urticaria (7%)
Nausea (8%)
Abdominal pain (56%)
Hyperhidrosis (23%)
Vertigo (9%)
Vomiting (6%)
Headache (6%)
Dyspnea (5%)
Pruritus (4%)
Asthenia (4%)
Musculoskeletal chest pain (4%)
Cough (4%)
Decreased appetite (3%)
Chest pain (3%)
Pyrexia (2%)
Jaundice (2%)
Chest discomfort (2%)
Constipation (< 2%)
Biliary colic (< 2%)
Arthralgia (< 2%)
Back pain (< 2%)
Spinal pain (< 2%)
Chromaturia (< 2%)
Sources:
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age 16.3 years
Health Status: unhealthy
Age Group: mean age 16.3 years
Sex: M+F
Sources:
Other AEs: Abdominal pain, Fatigue...
Other AEs:
Abdominal pain (grade 1, 100%)
Fatigue (grade 1, 50%)
Headache (grade 1-2, 75%)
Diarrhea (grade 1, 25%)
Nausea (grade 1, 75%)
Vomiting (grade 1, 25%)
Fever (grade 1-2, 25%)
Dizziness (grade 1, 50%)
Sources:
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age14.4 years
Health Status: unhealthy
Age Group: mean age14.4 years
Sex: M+F
Sources:
Other AEs: Abdominal pain, Fatigue...
Other AEs:
Abdominal pain (grade 1-2)
Fatigue (grade 1)
Headache (grade 1-2)
Diarrhea (grade 1-2)
Vomiting (grade 1)
Fever (grade 1-2)
Dizziness (grade 1)
Sources:
AEs

AEs

AESignificanceDosePopulation
Headache 10.6%
10 mg/kg 1 times / 8 hours multiple, oral
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 12-60 years
Health Status: unhealthy
Age Group: 12-60 years
Sex: M+F
Sources:
Jaundice 2.1%
10 mg/kg 1 times / 8 hours multiple, oral
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 12-60 years
Health Status: unhealthy
Age Group: 12-60 years
Sex: M+F
Sources:
Dizziness 4.3%
10 mg/kg 1 times / 8 hours multiple, oral
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 12-60 years
Health Status: unhealthy
Age Group: 12-60 years
Sex: M+F
Sources:
Abdominal pain 6.4%
10 mg/kg 1 times / 8 hours multiple, oral
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 12-60 years
Health Status: unhealthy
Age Group: 12-60 years
Sex: M+F
Sources:
Abdominal pain 1.3%
10 mg/kg 1 times / 8 hours multiple, oral
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 4-68 years
Health Status: unhealthy
Age Group: 4-68 years
Sex: M+F
Sources:
Diarrhea 1.3%
10 mg/kg 1 times / 8 hours multiple, oral
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 4-68 years
Health Status: unhealthy
Age Group: 4-68 years
Sex: M+F
Sources:
Fever 1.9%
10 mg/kg 1 times / 8 hours multiple, oral
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 4-68 years
Health Status: unhealthy
Age Group: 4-68 years
Sex: M+F
Sources:
Dizziness 5.4%
10 mg/kg 1 times / 8 hours multiple, oral
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 4-68 years
Health Status: unhealthy
Age Group: 4-68 years
Sex: M+F
Sources:
Diarrhea 2.9%
10 mg/kg 1 times / 8 hours multiple, oral
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 5-54 years
Health Status: unhealthy
Age Group: 5-54 years
Sex: M+F
Sources:
Vomiting 2.9%
10 mg/kg 1 times / 8 hours multiple, oral
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 5-54 years
Health Status: unhealthy
Age Group: 5-54 years
Sex: M+F
Sources:
Abdominal pain 5.7%
10 mg/kg 1 times / 8 hours multiple, oral
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 5-54 years
Health Status: unhealthy
Age Group: 5-54 years
Sex: M+F
Sources:
Headache 5.7%
10 mg/kg 1 times / 8 hours multiple, oral
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 5-54 years
Health Status: unhealthy
Age Group: 5-54 years
Sex: M+F
Sources:
Urticaria grade 1-2, 2.4%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Epigastric pain grade 1-2, 42.7%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Biliary colic grade 1-2, 49%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Pruritus grade 1-2, 6.1%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Jaundice grade 1-2, 7.2%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Fever grade 1-2, 8.5%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Nausea grade 1-2, 8.5%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Abdominal pain grade 3, 1.2%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Urticaria 11%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Headache 14%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Decreased appetite 18%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Nausea 18%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Hyperhidrosis 25%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Musculoskeletal chest pain 4%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Pruritus 4%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Diarrhea 7%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Vomiting 7%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Abdominal pain 93%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
ALT increased 3%
15 mg/kg single, oral
Recommended
Dose: 15 mg/kg
Route: oral
Route: single
Dose: 15 mg/kg
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Alkaline phosphatase increased 4.2%
15 mg/kg single, oral
Recommended
Dose: 15 mg/kg
Route: oral
Route: single
Dose: 15 mg/kg
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
AST increased 4.5%
15 mg/kg single, oral
Recommended
Dose: 15 mg/kg
Route: oral
Route: single
Dose: 15 mg/kg
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Bilirubin increased 6.8%
15 mg/kg single, oral
Recommended
Dose: 15 mg/kg
Route: oral
Route: single
Dose: 15 mg/kg
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Chest discomfort 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Jaundice 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Pyrexia 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Hyperhidrosis 23%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Chest pain 3%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Decreased appetite 3%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Asthenia 4%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Cough 4%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Musculoskeletal chest pain 4%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Pruritus 4%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Dyspnea 5%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Abdominal pain 56%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Headache 6%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Vomiting 6%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Urticaria 7%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Nausea 8%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Vertigo 9%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Arthralgia < 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Back pain < 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Biliary colic < 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Chromaturia < 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Constipation < 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Spinal pain < 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
Health Status: unhealthy
Age Group: adult | children
Sex: M+F
Sources:
Abdominal pain grade 1, 100%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age 16.3 years
Health Status: unhealthy
Age Group: mean age 16.3 years
Sex: M+F
Sources:
Diarrhea grade 1, 25%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age 16.3 years
Health Status: unhealthy
Age Group: mean age 16.3 years
Sex: M+F
Sources:
Vomiting grade 1, 25%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age 16.3 years
Health Status: unhealthy
Age Group: mean age 16.3 years
Sex: M+F
Sources:
Dizziness grade 1, 50%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age 16.3 years
Health Status: unhealthy
Age Group: mean age 16.3 years
Sex: M+F
Sources:
Fatigue grade 1, 50%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age 16.3 years
Health Status: unhealthy
Age Group: mean age 16.3 years
Sex: M+F
Sources:
Nausea grade 1, 75%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age 16.3 years
Health Status: unhealthy
Age Group: mean age 16.3 years
Sex: M+F
Sources:
Fever grade 1-2, 25%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age 16.3 years
Health Status: unhealthy
Age Group: mean age 16.3 years
Sex: M+F
Sources:
Headache grade 1-2, 75%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age 16.3 years
Health Status: unhealthy
Age Group: mean age 16.3 years
Sex: M+F
Sources:
Dizziness grade 1
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age14.4 years
Health Status: unhealthy
Age Group: mean age14.4 years
Sex: M+F
Sources:
Fatigue grade 1
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age14.4 years
Health Status: unhealthy
Age Group: mean age14.4 years
Sex: M+F
Sources:
Vomiting grade 1
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age14.4 years
Health Status: unhealthy
Age Group: mean age14.4 years
Sex: M+F
Sources:
Abdominal pain grade 1-2
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age14.4 years
Health Status: unhealthy
Age Group: mean age14.4 years
Sex: M+F
Sources:
Diarrhea grade 1-2
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age14.4 years
Health Status: unhealthy
Age Group: mean age14.4 years
Sex: M+F
Sources:
Fever grade 1-2
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age14.4 years
Health Status: unhealthy
Age Group: mean age14.4 years
Sex: M+F
Sources:
Headache grade 1-2
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age14.4 years
Health Status: unhealthy
Age Group: mean age14.4 years
Sex: M+F
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
yes [Ki 0.009 uM]
yes [Ki 0.016 uM]
yes [Ki 0.018 uM]
yes [Ki 0.05 uM]
yes [Ki 0.053 uM]
yes [Ki 0.061 uM]
yes [Ki 0.149 uM]
yes [Ki 0.166 uM]
yes [Ki 0.22 uM]
yes [Ki 0.37 uM]
yes [Ki 0.57 uM]
yes [Ki 0.75 uM]
yes [Ki 1.03 uM]
yes [Ki 1.27 uM]
yes [Ki 1.81 uM]
yes [Ki 12.5 uM]
yes [Ki 13 uM]
yes [Ki 2.31 uM]
yes [Ki 2.77 uM]
yes [Ki 4.32 uM]
yes
yes
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[A clinical trial of triclabendazole in the treatment of human paragonimiasis skrjabini].
2001
The biochemical basis of anthelmintic action and resistance.
2001 Apr
Effect of fasciolicides on the antigenaemia in sheep naturally infected with Fasciola hepatica.
2001 Aug
Efficacy of combined chemotherapy against gastrointestinal nematodes and Fasciola hepatica in cattle.
2001 Aug 20
An experimental study on triclabendazole resistance of Fasciola hepatica in sheep.
2001 Feb
Imported Fasciola hepatica infection in the United States and treatment with triclabendazole.
2001 Jul 1
[Stomach ache and fever after consumption of watercress in Turkey: fascioliasis].
2001 Sep 29
A comparative study on the effect of praziquantel and triclabendazole on Vampirolepis nana in vitro.
2002 Apr
Fasciola gigantica: tegumental surface alterations following treatment in vitro with the sulphoxide metabolite of triclabendazole.
2002 Apr
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 12-2002. A 50-year-old man with eosinophilia and fluctuating hepatic lesions.
2002 Apr 18
[Chilhood hepatic fascioliasis treated with triclabendazol].
2002 Aug
Pathological and immunohistochemical study of the liver and hepatic lymph nodes of sheep chronically reinfected with Fasciola hepatica, with or without triclabendazole treatment.
2002 Jul
A praziquantel-ineffective fascioliasis case successfully treated with triclabendazole.
2002 Jun
Triclabendazole-resistant Fasciola hepatica: beta-tubulin and response to in vitro treatment with triclabendazole.
2002 Mar
Synthesis and fasciolicidal activity of 5-chloro-2-methylthio-6-(1-naphthyloxy)-1H-benzimidazole.
2002 May
Development and validation of a liquid chromatographic-electrospray tandem mass spectrometric multiresidue method for anthelmintics in milk.
2002 Nov 8
Effects of three anthelmintic treatment regimes against Fasciola and nematodes on the performance of ewes and lambs on pasture in the highlands of Kenya.
2002 Oct
Fasciola hepatica infestation with joint symptoms.
2003 Feb
Pre-exposure of cattle to drug-abbreviated Fasciola hepatica infections: the effect upon subsequent challenge infection and the early immune response.
2003 Jan 20
Pediatric fascioliasis: report of three cases.
2003 Jan-Mar
Triclabendazole in the treatment of Paragonimiasis skrjabini.
2003 Nov
Clastogenic effects of the fasciolicide drug fasinex on river buffalo lymphocyte cultures in vitro.
2003 Nov 10
The effect of metronidazole in treating human fascioliasis.
2003 Oct
Human infection by Fasciola hepatica in Venezuela: report of a geriatric case.
2003 Sep
The effect of the microtubule inhibitor tubulozole-C on the tegument of triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica.
2003 Sep
Field trial on the efficacy of an experimental fasciolicide compared with some commercial compounds in naturally infected cattle.
2003 Sep
Chemotherapy for major food-borne trematodes: a review.
2004 Aug
Liver, spleen, pancreas and kidney involvement by human fascioliasis: imaging findings.
2004 Aug 4
Response of two isolates of Fasciola hepatica to treatment with triclabendazole in vivo and in vitro.
2004 Dec
Comparative assessment of the access of albendazole, fenbendazole and triclabendazole to Fasciola hepatica: effect of bile in the incubation medium.
2004 Jan
Human fascioliasis.
2004 May
Randomized trial of a single, double and triple dose of 10 mg/kg of a human formulation of triclabendazole in patients with fascioliasis.
2004 Nov
Fascioliasis imported to Norway.
2005
Triclabendazole for the treatment of fascioliasis and paragonimiasis.
2005 Dec
Separation and characterization of synthetic impurities of triclabendazole by reversed-phase high-performance liquid chromatography/electrospray ionization mass spectrometry.
2005 Feb 7
Eurytrema pancreaticum: the in vitro effect of praziquantel and triclabendazole on the adult fluke.
2005 Nov
Emerging foodborne trematodiasis.
2005 Oct
Altered drug influx/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes.
2005 Oct
Treatment of fascioliasis in human infections.
2006 Feb
Eight cases of fascioliasis: clinical and microbiological features.
2006 Jan
[Hepatobiliary fasciolasis without eosinophilia].
2006 Oct
[New drugs against parasitic diseases].
2007 Jan 31
Food-borne trematodiasis: current chemotherapy and advances with artemisinins and synthetic trioxolanes.
2007 Nov
[Fascioliasis: a 23-year retrospective study].
2007 Nov
Patents

Sample Use Guides

10 mg per kg of body weight as a single dose
Route of Administration: Oral
Triclabendazole was tested in vitro against recently excysted metacercariae. Triclabendazole was evaluated at concentrations of 10 and 50 mg/L., Triclabendazole demonstrated a fasciolicidal efficacy of 100% at a concentration of 10 and 50 mg/L at 24, 48 h and 72 hours post-treatment
Substance Class Chemical
Created
by admin
on Fri Jun 25 22:13:15 UTC 2021
Edited
by admin
on Fri Jun 25 22:13:15 UTC 2021
Record UNII
4784C8E03O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRICLABENDAZOLE
INN   MART.   MI  
USAN   INN  
Official Name English
1H-BENZIMIDAZOLE, 6-CHLORO-5-(2,3-DICHLOROPHENOXY)-2-(METHYLTHIO)-
Systematic Name English
NVP-EGA230
Code English
TRICLABENDAZOLE [MART.]
Common Name English
TRICLABENDAZOLE [ORANGE BOOK]
Common Name English
EGATEN
Brand Name English
TRICLABENDAZOLE [INN]
Common Name English
EGA230B
Code English
TRICLABENDAZOLE [MI]
Common Name English
5-CHLORO-6-(2,3-DICHLOROPHENOXY)-2-(METHYLTHIO)-1H-BENZIMIDAZOLE
Systematic Name English
TRICLABENDAZOLE [WHO-DD]
Common Name English
FASINEX
Brand Name English
TRICLABENDAZOLE [USAN]
Common Name English
NSC-759250
Code English
Classification Tree Code System Code
WHO-VATC QP52AC01
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
WHO-ATC P02BX04
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
FDA ORPHAN DRUG 564216
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.1.3
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
NCI_THESAURUS C250
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
FDA ORPHAN DRUG 525416
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
Code System Code Type Description
CAS
68786-66-3
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
EVMPD
SUB11267MIG
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
NCI_THESAURUS
C75236
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
MERCK INDEX
M11087
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY Merck Index
MESH
C039276
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
DRUG CENTRAL
2734
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
EPA CompTox
68786-66-3
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
RXCUI
2118525
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
LACTMED
Triclabendazole
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
FDA UNII
4784C8E03O
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
DRUG BANK
DB12245
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
ChEMBL
CHEMBL1086440
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
PUBCHEM
50248
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
INN
5003
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
WIKIPEDIA
TRICLABENDAZOLE
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
MAJOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
TARGET ORGANISM->INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
TARGET ORGANISM->INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE ACTIVE -> PARENT
MAJOR
PLASMA
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
FOR VETERINARY USE
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
FOR VETERINARY USE
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
FOR VETERINARY USE
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC